# Spevatamig

Source: https://onco.cc/drugs/spevatamig/  
OnCo record `spevatamig` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Spevatamig is an experimental bispecific antibody from Phanes Therapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and biliary tract cancer, aimed at Claudin 18.2 and CD47.

## Summary

Spevatamig (PT886) is a bispecific antibody developed by Phanes Therapeutics. Its targets are Claudin 18.2 and CD47. ClinicalTrials.gov describes the intervention as: Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and biliary tract cancer. The largest, NCT05482893, plans to enrol 258 participants with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: Spevatamig (PT886)
- Tags: pipeline; ctgov-ingest
- Code: PT886
- Modality: bispecific antibody
- Mechanism: Bispecific antibody directed at Claudin 18.2 and CD47, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of Spevatamig: https://clinicaltrials.gov/search?intr=PT886

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [CD47](https://onco.cc/targets/cd47/), [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- companies: [Phanes Therapeutics](https://onco.cc/companies/phanes-therapeutics/)
- trials: [Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junct](https://onco.cc/trials/nct05482893/)

---
JSON: https://onco.cc/api/v1/entities/spevatamig.json